Key developments from recent financial reports and clinical trial updates include:
- ADC Therapeutics announced promising results for its CD19-directed ADC, Zynlonta, showing a 95.5% overall response rate in patients with relapsed/refractory DLBCL, but has halted development of ADCT-602.
- Elevation Oncology reported a wider net loss of $14 million for Q1 2025 and is discontinuing the development of EO-3021 alongside a significant workforce reduction.
- Mersana Therapeutics is restructuring to extend its cash runway while focusing on the development of emiltatug ledadotin.
- Sutro Biopharma posted a larger net loss of $76 million for Q1 2025, as compared to the previous year.
- ImmunityBio saw a substantial increase in net product revenue to approximately $17 million, driven by a 150% rise in Anktiva unit sales.
- Mural Oncology noted an 18% increase in short interest, while Nektar Therapeutics reported a net loss of $51 million, and Werewolf Therapeutics reported an $18 million loss but remains on schedule for trial data readouts.
- Allogene Therapeutics and Autolus Therapeutics reported losses of $60 million and $70 million respectively, with the latter gaining European approval for its therapy.
- Arcellx presented strong data from its iMMagine-1 study for treating multiple myeloma, achieving a 97% overall response rate without serious delayed neurotoxicities.
- Immutep reported that its trial of efti in combination with radiotherapy exceeded its primary endpoint in soft tissue sarcoma.
- MacroGenics showed a reduced loss of $41 million in Q1 2025 compared to the previous year.
Overall, the biotech sector experiences various financial challenges while several companies continue to advance clinical programs and report positive trial results.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ppf.eu/insights/biotech-market/may-2025-biotechnology-review-of-news-from-the-most-innovative-therapeutic-areas/stocks-tumbled-as-sweeping-tax-and-spending-bill-could-dramatically-increase-fede
